Navigation Links
Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
Date:9/15/2010

SILVER SPRING, Md., Sept. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration (FDA), working in close coordination with the U.S. Department of Justice (USDOJ), today announced that Forest Pharmaceuticals, Inc. entered into a plea agreement in which the company accepted responsibility for criminal actions including distribution of an unapproved new drug, distribution of a misbranded drug, and obstruction of an FDA inspection.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

To resolve these charges and a related civil suit, Forest Pharmaceuticals, Inc. has agreed to pay more than $300 million, including $164 million in criminal penalties. This plea agreement is the culmination of a multiyear investigation conducted by FDA's Office of Criminal Investigations in cooperation with its law enforcement partners and the U.S. Attorney's Office for the District of Massachusetts.

Charges against Forest Pharmaceuticals, Inc. are primarily for its marketing of Levothroid (levothyroxine sodium tablets, USP), an unapproved drug used for the treatment of hypothyroidism. A 1997 Federal Register notice announced that these products are considered "new drugs" within the meaning of the Federal Food Drug and Cosmetic Act (FDCA) and that manufacturers who wished to continue marketing these products must obtain approved applications from the FDA by August 2000. Because levothyroxine was considered a medically necessary product, the FDA permitted a gradual phase-out with all distribution of unapproved levothyroxine sodium drug products to cease no later than August 2003.

Forest Pharmaceuticals did not obtain drug approval, increased its distribution of Levothroid rather than scaling down, and ignored a subsequent Warning L
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 CytRx Corporation (NASDAQ: ... company specializing in oncology, announced that data regarding the ... the treatment of first-line soft tissue sarcoma (STS) will ... 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting which ... Berlin , Germany. Due to the longer than expected ...
(Date:10/16/2014)... Oct. 16, 2014  Cepheid (Nasdaq: CPHD ... 2014 of $115.2 million, representing growth of 15% from ... loss in the third quarter of 2014 was $(7.2) ... loss of $(1.4) million, or $(0.02) per share, in ... stock-based compensation expense, amortization of debt discount and transaction ...
(Date:10/16/2014)... , Oct. 16, 2014   DaVita HealthCare ... one of the nation,s largest and most innovative ... Institute ranked DaVita HealthCare Partners 37 th ... recent article in Harvard Business Review ... , which evaluates companies based on reputation strength, ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Harvard Business Review Recognizes DaVita HealthCare Partners 2Harvard Business Review Recognizes DaVita HealthCare Partners 3
... 3, 2010 The Amgen Foundation will grant $4.5 million ... to invest in "LA,s Promise" – an endeavor to prepare ... college and a healthier, more successful life.   ... see an entire community,s children ready for college and life," ...
... College of Radiology (ACR) distributed 1,500 copies of the College,s ... free of charge to physicians in approximately 600 ACR-accredited mammography ... Case Review ( MCR5 ), a self-evaluation educational tool, ... detection of cancers and other abnormalities via mammography by allowing ...
Cached Medicine Technology:Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise 2Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise 3ACR Distributes Free High-Tech Mammography Education Tool to NY Facilities 2
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... NATIONS, New York (PRWEB) October 19, 2014 ... United Nations Population Fund, welcomes news of a ceasefire ... of the more than 200 girls who were kidnapped ... "These girls have languished in captivity long enough, and ... families, schools and communities," stated Dr. Osotimehin. , "We ...
(Date:10/19/2014)... 2014 SweetDressy.com, a professional company of ... promotion for long evening dresses . All the ... offer; the current discount is up to 66 percent ... pioneers in the fashion field. Its dress specialists are ... in various parts of the world. All the company’s ...
(Date:10/19/2014)... The U.S. Government has initiated a major effort ... 2025. However, a workgroup of nearly 40 Alzheimer,s ... the U.S. Government,s National Plan to Address Alzheimer,s ... scale, and adequately funded in order to successfully ... the workgroup to enlarge and strengthen the Plan ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... The American School,Health Association, the National Association of ... today joined together to create,one voice to urge ... Prevention,and Tobacco Control Act, which would give the ... three associations, each formed to assist the Nation,s ...
... representatives are invited,to a photo opportunity with the Honourable ... Governor, in light of an,international collaboration announcement on cancer ... Convention in San Diego., Who: ... Arnold Schwarzenegger, The ...
... Inc.,(Nasdaq: HOLX ) today announced that Glenn Muir, ... Annual Healthcare Conference being,held June 24 - 26, 2008, ... Interested parties are invited to listen to a ... 25, 2008, at 12:30 PM.,Eastern Time on the investor ...
... also express concern about psoriasis drug,s possible risks for ... strengthening , , WEDNESDAY, June 18 (HealthDay News) -- ... Wednesday that the psoriasis drug Enbrel be approved for ... skin disease. , The outside medical experts, in a ...
... higher annual volumes of patients with inflammatory bowel disease ... than hospitals with lower volumes of IBD patients, according ... College of Wisconsin in Milwaukee. ,The study ... for patients who undergo surgery for Crohn,s Disease, a ...
... SF-12v2 Health Survey Results are Used to Measure Physical ... and Mental Health Status of Program Participants, ... the,SilverSneakers(R) Fitness Program was created to encourage older adults ... the nation,s leading,fitness program aimed exclusively at older adults. ...
Cached Medicine News:Health News:Major Associations Band Together to Urge Congressional Action on Tobacco Legislation 2Health News:Hologic to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 3Health News:Choice of hospital impacts outcomes for inflammatory bowel disease surgery 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 3
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... AnchorSew™ 3 mm is a resorbable repair device ... ArthroSew suturing device to attach soft tissue to ... into a prepared hole in the bone, and ... tissue anchors are made of a resorbable copolymer, ...
... is generally used when anchor size ... anchor is packaged sterile and comes ... and needles. Although pre-drilling is not ... Harpoon®, 1.6mm & 1.8mm drills are ...
Medicine Products: